Skip to content

Pilot Evaluation to Assess the Clinical and Economic Impact of Pfizer's Pain Management Program (painPREMIER) in the Treatment of Low Back Pain, in an Occupational Health Care Setting in Finland

Pilot Evaluation to Assess the Clinical and Economic Impact of Pfizer's Pain Management Program (painPREMIER) in the Treatment of Low Back Pain, in an Occupational Health Care Setting in Finland

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01787565
Enrollment
86
Registered
2013-02-08
Start date
2013-01-31
Completion date
2014-01-31
Last updated
2016-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Back Pain

Keywords

non-interventional, clinical, investigation, low, back, pain, painPREMIER

Brief summary

The aim of this investigation is to determine whether the use of painPREMIER will significantly improve function in patients with low back pain in an occupational health clinical setting. painPREMIER is a tool that assists clinicians in the accurate diagnosis of back pain and associated problems in order to treat them most effectively.

Detailed description

Patients presenting at feeder sites to be referred to low back pain clinic and assessed for eligibility A decision was made to terminate this study on 09 OCT 2013. The study was terminated for operational/business reasons. This study was not terminated for reasons of safety or efficacy.

Interventions

Low back pain patients prospectively recruited during the study period and managed with painPREMIER.

A matched group of low back pain patients not managed with painPREMIER.

Sponsors

Terveystalo
CollaboratorOTHER
Pfizer
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* New episode of low back pain * Member of Terveystalo health insurance scheme

Exclusion criteria

* Previous back pain related healthcare visit in the last 3 months * Patients identified as having a 'red flag' condition

Design outcomes

Primary

MeasureTime frameDescription
Roland Morris Disability Questionnaire3 monthsChange from baseline

Secondary

MeasureTime frameDescription
SF-12 (Short Form 12 Health Survey), v2.0 (Mental Component Summary Scale and Physical Component Summary Scale)3 monthsChange from baseline
EQ5-D Health Questionnaire3 monthsChange from baseline
PHQ-4 (Patient Health Questionnaire for Depression and Anxiety-4)3 monthsProportion of patients at risk for depression and/or anxiety
Self-reported depression PHQ-8 (Patient Health Questionnaire for Depression and Anxiety-8) and anxiety GAD-7 (Generalized Anxiety Disorder 7-item scale)3 monthsChanges from baseline (if collected at BL)
Roland Morris Disability Questionnaire6 monthsChange from baseline
Self-reported low back pain intensity3 monthsChange from baseline
Self-reported low back pain intensity and Roland Morris Disability Questionnaire3 monthsProportion of patients with at least 30% and 50% improvement
Self-reported catastrophizing - Coping Strategies Questionnaire - Catastrophizing scale (CSQ-CAT)3 monthsChanges from baseline
Self-reported absenteeism, presenteeism, lost productivity and activity, over prior 2 weeks, measured by Work Productivity and Activity Impairment (WPAI): Specific Helath Problem (Low Back Pain) questionnaire (painPREMIER cohort)3 monthsChanges from baseline
All-cause absence days and costs associated with sick leave3 monthsComparison between painPREMIER cohort and control cohort
All-cause pharmacy and medical resource use/costs3 monthsComparison of pre and post-enrollment for both cohorts
Low back pain-related medical resource use/costs and pharmacy use/costs3 monthsComparison of pre and post-enrollment for both cohorts
Low back pain-specific medical resource use/costs3 monthsComparison of pre and post-enrollment for both cohorts
Total low back pain direct medical costs3 monthsComparison of pre and post-enrollment for both cohorts
Global Assessment of Disease Activityany time up to 6 monthsChange from baseline
Overall all costs via claims and absence data3 monthsComparison between painPREMIER and control cohort
Patient Satisfaction3 monthsPatient Satisfaction with painPREMIER
Specialist Occupational Health Provider SatisfactionAfter enrolment complete estimated 4 monthsSpecialist Occupational Health Provider Satisfaction with painPREMIER
Net Promoter Score1 weekNet Promoter Score
Semi-structured interview6 monthsPatient feedback
Specialist Occupational Health Provider Engagement6 monthsSpecialist Occupational Health Provider Engagement with portal
Specialist Occupational Health Provider treatment recommendations6 monthsSpecialist Occupational Health Provider treatment recommendations vs painPREMIER treatment recommendations
Patient engagement/treatment adherence6 monthsPlatform use, CBST(Cognitive Behavioral Skills Training) module use and adherence to pharmacological therapy
TAMPA17 Scale for Kinesiophobia, PHQ4, PHQ8, (Patient Health Questionnaire for Depression and Anxiety-4 and 8), GAD7 (Generalized Anxiety Disorder 7-item scale)BaselineTo evaluate the correlation between TAMPA17, PHQ4, PHQ8, GAD7 baseline assessments in the painPREMIER cohort
painDETECT, TAMPA17 Scale for Kinesiophobia, LBPI (low back pain intensity) and RMDQ (Roland Morris Disability Questionnaire)3 monthsTo evaluate the change from baseline and correlation between the instruments in the painPREMIER cohort
Sub-group analysis6 monthsTo evaluate patterns of use and outcomes in subgroups
Daily sleep intereference rating scale3 monthsChange from baseline
Self-reported catastrophizing (CSQ-CAT) Coping Strategies Questionnaire - Catastrophizing scale6 monthsChange from baseline
Overall low back pain costs via claims data and imputed WPAI:LBP Work Productivity and Activity Impairment (WPAI): Specific Helath Problem (Low Back Pain) questionnaire3 monthsComparison between painPREMIER and control cohort

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026